Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis

Journal of Bone and Mineral Research

Volumn 19, Issue 11, 2004, Pages 1797-1804

  Frost, Michelle L ^a   Fogelman, Ignac ^a   Blake, Glen M ^a   Marsden, Paul K ^b   Cook, Gary J R ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bone formation; Bone turnover markers; Osteoblasts; Osteoporosis; Positron emission tomography

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; FLUORODEOXYGLUCOSE F 18; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BLOOD FLOW; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE REMODELING; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMAGE ANALYSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NON INVASIVE MEASUREMENT; OSSIFICATION; OSTEOBLAST; OSTEOPENIA; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUANTITATIVE ANALYSIS; SCORING SYSTEM; AGED; BONE; IMAGE PROCESSING; KINETICS; LUMBAR VERTEBRA; METABOLIC BONE DISEASE; MIDDLE AGED; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGY; RADIODENSITOMETRY; THEORETICAL MODEL; TIME;

AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; BONE RESORPTION; DENSITOMETRY, X-RAY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KINETICS; LUMBAR VERTEBRAE; MIDDLE AGED; MODELS, THEORETICAL; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; POSITRON-EMISSION TOMOGRAPHY; POSTMENOPAUSE; RADIOPHARMACEUTICALS; TIME FACTORS;

EID: 16644393621     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040818     Document Type: Article

References (46)

1. Heaney RP 2003 Is the paradigm shifting? Bone 33:457-465.
2. Garnero P, Sornay-Rendu E, Duboef F, Delmas PD 1999 Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11(Suppl 6):S55-S65.
3. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA 2002 Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 13:523-526.
4. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
5. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
6. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
7. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592.
8. Delmas PD 1993 Biochemical markers of bone turnover. J Bone Miner Res 8:S2;S549-S555.
9. 99mTc- Methylene diphosphonate. J Nucl Med 43:338-345.
10. Fogelman I, Bessent RG, Turmer JG, Citrin DL, Boyle IT, Grieg WR 1978 The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 19:270-275.
11. 99mTc-diphosphonate. Relation to biochemical indices of bone turnover and to total body calcium. Eur J Nucl Med 13:32-35.
12. 18F-fluoride positron emission tomography in postmenopausal women. J Bone Miner Res 15:763-769.
13. Hawkings RA, Choi Y, Huang S-C, Hoh CK, Dahlbom M, Schiepers C, Satyamurthy N, Barrio JR, Phelps ME 1992 Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 33:633-642.
14. Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, Verbruggen A, de Roo M 1997 Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 38:1970-1976.
15. 18F-fluoride PET: Correlation with bone histomorphometry. J Nucl Med 42:1091-1100.
16. 18F-fluoride ion in renal osteodystophy: Correlation with bone histomorphometry. J Clin Endocrinol Metab 77:949-955.
17. 18F-fluoride positron emission tomography. J Bone Miner Res 18:2215-2222.
18. Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL 1988 Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 67:741-748.
19. Fogelman I, Bessent R 1982 Age-related alterations in skeletal metabolism - 24-hr whole-body retention of disphosphonate in 250 normal subjects: Concise communication. J Nucl Med 23:296-300.
20. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349.
21. Eastell R, Robins SP, Colwell T, Assiri AMA, Riggs BL, Russell RGG 1993 Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 3:255-260.
22. Kushida K, Takahashi M, Kawana K, Inoue T 1995 Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80:2447-2450.
23. Arlot ME, Delmas PD, Chappard D, Meunier PJ 1990 Trabecular and endocortical bone remodelling in postmenopausal osteoporosis: Comparison with normal postmenopausal women. Osteoporos Int 1:41-49.
24. Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL 1990 Cancellous bone remodelling in type I (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res 5:311-319.
25. Garcia-Carasco M, de Vernejoul MC, Sterkers Y, Morieux C, Kuntz D, Miravet L 1989 Decreased bone formation in osteoporotic patients compared with age-matched controls. Calcif Tissue Int 44:173-175.
26. Kimmel DB, Recker RR, Gallagher JC, Vaswani AS, Aloia JF 1990 A comparison of iliac bone histomorphometric data in postmenopausal osteoporotic and normal subjects. Bone Miner 11:217-235.
27. Parfitt AM, Villanueva AR, Foldes J, Sudhaker-Rao D 1995 Relations between histologic indices of bone formation: Implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res 10:466-473.
28. Compston JE, Croucher PI 1991 Histomorphometric assessment of trabecular bone remodelling in osteoporosis. Bone Miner 14:91-102.
29. World Health Organization 1994 Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Technical Support Series No. 843. World Health Organization, Geneva, Switzerland.
30. Carter DR, Bouxsein ML, Marcus R 1992 New approaches for interpreting projected bone densitometry data. J Bone Miner Res 7:137-145.
31. Cook GJR, Lodge MA, Marsden PK, Dynes A, Fogelman I 1999 Non-invasive assessment of skeletal kinetics using fluorine-18-fluoride positron emission tomography: Evaluation of image and population-derived arterial input functions. Eur J Nucl Med 26:1424-1429.
32. 18F-fluoride positron emission tomography. J Bone Miner Res 17:854-859.
33. 18F-fluoride ion PET and quantitative CT. J Nucl Med 44:117-124.
34. Parfitt AM 1996 Skeletal heterogeneity and the purposes of bone remodelling. Implications for the understanding of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.) Osteoporosis. Academic Press, San Diego, CA, USA, pp. 315-329.
35. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C 1988 Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment. J Clin Invest 82:1268-1274.
36. 99mTechnetium-Tin- Methylene diphosphonate in normal subjects and pathological conditions: A simple index of bone metabolism. Calcif Tissue Int 30:5-13.
37. 99mTc-MDP retention in osteoporosis: Relationship to other indices of bone cell activity and response to calcium and vitamin D therapy. Eur J Nucl Med 13:462-466.
38. 99mTc-methylene diphosphonate with age: Relevance to the pathogenesis of bone loss. J Nucl Med 41:1478-1483.
39. Israel O, Lubushitzky R, Frenkel A, Iosilevsky G, Bettman L, Gips S, Hardoff R, Baron E, Barzilai D, Kolodny GM, Front D 1994 Bone turnover in cortical and trabecular bone in normal women and in women with osteoporosis. J Nucl Med 35:1155-1158.
40. Lips P, Courpron P, Meunier PJ 1978 Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age. Calcif Tissue Int 10:13-17.
41. Ishiguro K, Nakagaki H, Tsuboi S, Narita N, Kato K, Li J, Kamei H, Yoshioka I, Miyauchi K, Hosoe H, Shimano R, Weatherell JA, Robinson C 1993 Distribution of fluoride in cortical bone of human rib. Calcif Tissue Int 52:278-282.
42. Narita N, Kato K, Nakagaki H, Ohno N, Kameyama Y, Weatherall JA 1990 Distribution of fluoride concentration in the rat's bone. Calcif Tissue Int 46:200-204.
43. Pødenphant J, Engel U 1987 Regional variations in histomorphometric bone dynamics from the skeleton of an osteoporotic woman. Calcif Tissue Int 40:184-188.
44. Peters AM, Myers MJ 1998 Body fluids, electrolytes and bone. In: Peters AM, Myers MJ (eds.) Physiological Measurements with Radionuclides in Clinical Practice. Oxford University Press, New York, NY, USA, pp. 262-278.
45. Mosekilde L, Hasling C, Charles P, Tågehøj Jensen F 1987 Bisphosphonate whole body retention test: Relations to bone mineralisation rate, renal function and bone mineral content in osteoporosis and metabolic bone disorders. Eur J Clin Invest 17:530-537.
46. 99mTc-MDP. Normalisation by bone mass. Scand J Clin Lab Invest 46:587-592.